512th Edition, June 14th, 2022

Trouble Viewing This Email: Click Here

June 14, 2022

FOUNDING MEMBER OF

BioHealth Innovation Announces Additions

ROCKVILLE, MARYLAND, June xx, 2022 – BioHealth Innovation Inc. (BHI) announces the additions of Anna Zornosa, MA, as an Entrepreneur-in-Residence (EIR) with the NIH Office of Extramural Research, and Aliye Hashemi, B.Sc., a BHI Analyst. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources.

“BHI is proud to welcome Anna and Aliye to the team,” said Richard Bendis, BHI President and CEO. “Anna brings a wealth of experience, and Aliye is ready to continue her impressive development with us.”

BHI Supports Maryland's showcase of life science assets at BIO International in San Diego

A delegation of Maryland companies and organizations is heading to San Diego June 13-16 for the BIO International Convention. At BIO, the life sciences industry’s leading trade show, Maryland will showcase the unparalleled life science assets within the state.

The Maryland Department of Commerce, in collaboration with the Maryland Tech Council, will exhibit at Booth #5013. The Maryland Department of Commerce, Maryland Tech Council and various sponsors are supporting a delegation of 15 Maryland life sciences companies’ attendance at the show. Companies in the Maryland delegation receive premium access to BIO, including its exhibit hall, educational program, and one-on-one partnering to meet with potential partners and investors. Companies in the Maryland delegation include:

BHI Attends BLUE KNIGHT Symposium 2022

BHI was pleased to join our partners at today's BLUE KNIGHT Symposium 2022 hosted at JLABS @ Washington, DC. Thanks to BARDA, Johnson & Johnson and all of the entrepreneurs and innovative minds who are strategizing today for tomorrow's public health challenges.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on June 15th and find out. To sign-up for any of the EIR dates in 2022, please follow this link.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

Novavax CEO Stanley Erck talks Covid-19 vaccine, FDA meeting — and what comes next – Washington Business Journal

The Gaithersburg biotech has had no product to market in its 35-year history.

QIAGEN CEO details how company tracks the spread of COVID through wastewater testing

QIAGEN CEO Thierry Bernard joins Yahoo Finance Live to explain how his company is utilizing technology to track the spread of COVID through wastewater and also discusses how to track the monkeypox outbreak.

Accurately testing wastewater for COVID could help cities and towns prepare for outbreaks, stock up supplies, or put measures in place to prevent further community transmission of COVID-19. And one company recently receiving a nod from the CDC for wastewater testing is German company QIAGEN.

United Therapeutics and 3D Systems shoot for 3D printed lung scaffold trials within five years – 3D Printing Industry

Biotechnology firm United Therapeutics has showcased what it claims to be the “world’s most complex 3D printed object” in partnership with 3D printer manufacturer 3D Systems at the recent LIFE ITSELF conference in San Diego.

The partners have produced a 3D printed human lung scaffold capable of demonstrating gas exchange in animal models, and are now planning to cellularize the scaffold with a patient’s own stem cells to create tolerable, transplantable human lungs.

Deka Biosciences, Inc is Growing

The Deka Biosciences team is now 17 strong – and growing!

Image: https://www.linkedin.com

Abu Dhabi Cements the Long-Standing Partnership with the Children's National Hospital in Washington DC

ABU DHABI, UAE , June 9, 2022 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate of Abu Dhabi, signed a Declaration of Collaboration with the Children's National Hospital, home to the Sheikh Zayed Institute for Pediatric Surgical Innovation, as part of the Abu Dhabi Life Science Mission to the USA.

The signing cements the long-standing partnership between Abu Dhabi and Children's National Hospital in Washington DC and facilitates both entities collaborating on three key areas including genomics and oncology research and other innovations to address pediatrics, diseases and patients' management. The agreement also explores establishing Abu Dhabi as a regional pediatric hub.

WIB-Capital Region: HERstory Gala 2022, April 21, 2022 – Women In Bio

The fourth annual HERstory Gala took place on Thursday, April 21, 2022 at the VisArt Studio in Rockville Town Square. This gala is the chapter’s premier event honoring outstanding women in biotech in the Washington DC metro region. Attendees included 85 members and supporters from diverse professional backgrounds, including science, marketing, legal, and entrepreneurship.

Image: https://www.womeninbio.org

Life Sciences Research Talent 2022 | CBRE – BHCR #2

The life sciences revolution remains robust.

A variety of megatrends (demographic, economic, technological, etc.) coupled with rapid advances in technology have boosted life sciences growth over the last decade. More recently, the COVID-19 pandemic catapulted the life sciences industry to a new level of prominence with cutting-edge innovations.

Fierce competition for talent—exacerbated by demographic changes, pandemic-induced burnout and shifting family responsibilities—presents challenges as the industry seeks to meet growing demand for its products and services.

Maryland Inno – Proposed USM program would fund early stage startups

The University System of Maryland may soon have a new pilot program to fund early stage startups.

The measure, which was approved by both the USM Board of Regents Committee on Economic Development and Technology Commercialization and the Committee on Finance on Thursday, would allocate $200,000 per year to the Early Capital Pilot fund over three years.

Image: The University System of Maryland may establish a new fund to help early stage entrepreneurs. Jessica Iannetta/BBJ

Healthcare Innovators Nurturing the Next Great Breakthroughs | Johnson & Johnson

Tackling health inequities. Pinpointing the sources of pain. Helping the immune system target cancer. These are just some of the ambitious goals of the companies residing at Johnson & Johnson's newest incubator, JLABS @ Washington, DC. Meet three healthcare innovators leading the way.

Image: https://www.jnj.com/

Inventions of the Year: UMD, JHU Researchers Develop AI-Enhanced Digital Otoscope for Diagnosing Pediatric Ear Disease | Division of Research

Ear infections, or the inflammation of the middle ear typically caused by bacteria, are a notorious nuisance in early childhood. The high incidence, recurrent nature, and non-specific presentation of ear infections in children have made it a feared diagnosis among parents. According to the National Institute on Deafness and Other Communication Disorders, ear infections are the most common reason for a trip to the pediatrician, with five out of six children experiencing at least one ear infection by age three, and 25% of children having repeated ear infections. Researchers at the University of Maryland (UMD), in collaboration with Johns Hopkins University (JHU), have developed an innovative technology that could save a trip to the doctor’s office by enabling virtually anyone to record and triage a child’s symptoms and status confidently and competently.

Image: Inventor John Rzasa Photo by Sage Levy

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in the U.S. GAITHERSBURG, Md., June 7, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over.

"The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "In today's VRBPAC meeting, we heard the overwhelming support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option. Consistent with submissions to regulatory authorities worldwide, we have already submitted an amendment with updated manufacturing information for the EUA to the FDA for review. We look forward to collaborating with the FDA as it makes its final decision."

About BioHealth Innovation

Contact

Connect